| INA03 |
INATHERYS |
Acute Lymphoblastic Leukemia |Acute Myeloid
Leukemia |
CD71 |
Early Phase I |
NCT03957915 |
| ABBV-319 |
AbbVie |
Diffuse Large B-Cell Lymphoma|Lymphocytic
Leukemia|Follicular Lymphoma |
CD19 |
Phase I |
NCT05512390 |
| CC-99712 |
Celgene |
Multiple Myeloma |
BCMA |
Phase I |
NCT04036461 |
| CS5001 |
CStone Pharmaceuticals |
Advanced Lymphoma |
PTK7 |
Phase I |
NCT05279300 |
| F0002 |
Shanghai
Fudan-Zhangjiang Bio-Pharmaceutical Co. |
CD30+ hematological
malignancies |
CD30 |
Phase I |
NCT03894150 |
| JBH492 |
Novartis |
Non-Hodgkin’s Lymphoma|Lymphocytic Leukemia |
CCR7 |
Phase I |
NCT04240704 |
| Moxetumomab Pasudotox |
National Cancer Institute |
Hairy Cell Leukemia |
CD22 |
Phase
I |
NCT03805932 |
| MRG001 |
Shanghai Miracogen |
B-cell Non-Hodgkin Lymphoma |
CD20 |
Phase I |
NCT05155839 |
| TRS005 |
Zhejiang
Teruisi Pharmaceutical |
B-cell Non-Hodgkin’s Lymphoma |
CD20 |
Phase I |
NCT05395533 |
| ADCT-602 |
ADC Therapeutics |
Acute Lymphoblastic Leukemia |
CD22 |
Phase I |Phase II |
NCT03698552 |
| BN301 |
BioNova Pharmaceuticals (Shanghai) |
Non Hodgkin’s Lymphoma|Diffuse Large B Cell Lymphoma|Follicular
Lymphoma |
CD74 |
Phase I |Phase II |
NCT05611853 |
| CX-2029 |
CytomX Therapeutics |
Diffuse Large B Cell Lymphoma |
CD71 |
Phase I |Phase II |
NCT03543813 |
| HDP-101 |
Heidelberg Pharma |
Multiple Myeloma|Plasma Cell Disorder |
BCMA |
Phase I |Phase II |
NCT04879043 |
| PRO1160 |
ProfoundBio |
Non Hodgkin’s
Lymphoma |
CD70 |
Phase I |Phase II |
NCT05721222 |
| STI-6129 |
Sorrento Therapeutics |
Multiple Myeloma |
CD38 |
Phase I |Phase II |
NCT05308225 |
| Trastuzumab Emtansine |
National Cancer
Institute |
Advanced Lymphoma|Refractory Plasma Cell Myeloma |
HER2 |
Phase II |
NCT04439110 |
| Zilovertamab vedotin |
Merck |
Diffuse Large B-Cell Lymphoma |
ROR1 |
Phase II |Phase III |
NCT05139017 |
| Belantamab mafodotin |
GlaxoSmithKline |
Multiple Myeloma |
BCMA |
Phase III |
NCT04162210 |
| Gemtuzumab Ozogamicin |
Gruppo Italiano Malattie
EMatologiche dell’Adulto |
Acute Myeloid Leukemia |
CD33 |
Phase III |
NCT04168502 |
| Loncastuximab Tesirine |
ADC Therapeutics |
Diffuse Large B-Cell Lymphoma |
CD19 |
Phase III |
NCT04384484 |
| Polatuzumab
Vedotin |
Hoffmann-La Roche |
Diffuse Large
B-Cell Lymphoma |
CD79 |
Phase III |
NCT03274492 |
| Brentuximab vedotin |
Takeda |
Anaplastic Large-cell Lymphoma |
CD30 |
Phase IV |
NCT01909934 |
| Inotuzumab ozogamicin |
Pfizer |
Leukemia| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
CD22 |
Phase IV |
NCT03677596 |
